Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06414746
Other study ID # D8451R00001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 29, 2023
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicenter observational study consisting of retrospective and prospective phases. The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who underwent surgery for CTS to assess their probability of having ATTR PN.


Description:

ATTR PN is a genotypically, phenotypically and geographically variable disease with a poor prognosis, albeit available disease-modifying drugs can change the disease trajectory. Thus country-specific epidemiologic data collection and identification of early stage PN, including previously misdiagnosed patients, is crucial to improve outcomes and quality of life. However, no observational studies on the epidemiology of ATTR PN in the whole Russian population, or in patients with CTS, have been performed. Therefore, there is a need to conduct a large-scale observational study to determine the prevalence of ATTR PN in Russia, obtain information on patients' clinical characteristics, and determine their medical needs. The approaches to diagnosis of ATTR PN in Russia over the past few years have been characterized by the use of heterogenous methods, partially explained by the lack of availability of molecular genetic testing, which is essential to diagnose the presence of pathogenic mutation in patients with hereditary ATTR PN. Thus, recent introduction of such tests into routine clinical practice may allow to assess reliable epidemiologic data including estimation of true ATTR PN prevalence among patients with CTS, which can often be the first manifestation of the disease. Earlier recognition, in turn, may lead to timely treatment initiation and change in the prognostic outlook of ATTR PN patients. In order to assess the prevalence of ATTR PN in patients undergoing surgery for CTS in Russia this study will retrospectively include patients with the diagnosis of CTS undergoing surgery between the 1st January 2021 and the 1st September 2024. Suspicion of ATTR PN will be assessed in each case, and diagnostic tests (comprehensive neurological examination including nerve conduction study (NCS) combined with molecular genetic testing) to confirm or exclude the disease will be conducted prospectively in eligible patients. In addition to that, clinical features, concomitant manifestations, and diagnosed genotypes will be analyzed to examine characteristic ATTR PN patient profiles in the Russian Federation.


Recruitment information / eligibility

Status Recruiting
Enrollment 880
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: for the retrospective phase are: 1. Patients with the established diagnosis of CTS undergoing surgical intervention between the 1st January 2021 and the 1st September 2024. 2. Age = 18 years at the time of surgery. Additional inclusion criteria for the prospective phase are: 3. Provided written informed consent for the prospective phase of the study (including molecular genetic testing). 4. Bilateral CTS; 5. Presence of =1 of the following features (red flags): 1. CIDP or polyneuropathy of unknown etiology in the family history; 2. Spinal canal stenosis of the lumbar region; 3. Autonomic dysfunction, defined by the presence of =1 of the following symptoms: i. gastrointestinal complaints (constipation, chronic diarrhea, or both); ii. erectile dysfunction; iii. orthostatic hypotension; 4. Gait disorders; 5. Sweating disorders, anhidrosis. 6. Paresthesia and burning of the skin of the distal extremities 7. Distal symmetrical paresis 8. Hypotrophy and hypotension of limb muscles, areflexia 9. Biceps tendon rupture 10. Aortic valve stenosis 11. Diagnosis of HFpEF 12. Unexplained weight loss =5 kilos at any timepoint since the onset of symptoms of CTS; 13. Left ventricular hypertrophy (based on electro- or echocardiographic criteria documented in the patient's medical record); 14. Heart rhythm disorders; 15. Renal abnormalities, defined by =1 of the following features - i. documented diagnosis of chronic kidney disease (CKD); ii. decreased estimated glomerular filtration rate (eGFR <60 mL/min/1.73m2); iii. increased serum creatinine (SCr) above reference range of the local laboratory; iv. albuminuria (=30 mg/g of creatinine or =30 mg/24h ); v. proteinuria (according to urinalysis results). 16. Ophthalmology disorder defined by =1 of the following features - i. vitreous body inclusions (opacification); ii. Glaucoma; iii. pupillary disorders; iv. vitrectomy 6. Absence of previously established ATTR PN diagnosis (ICD-10 code ?85.1, "Neuropathic hereditary familial amyloidosis"). Exclusion Criteria: for the retrospective phase are: 1. Participation in any interventional trial within the period since surgical intervention until the end of current study. Additional exclusion criteria for the prospective phase are: 2. Previously performed TTR genetic testing; 3. Verified B12 deficiency; 4. History of alcohol abuse according to the patient's medical record.

Study Design


Locations

Country Name City State
Russian Federation Research Site Moscow
Russian Federation Research Site Saint-Petersburg

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary To define the prevalence of ATTR PN in patients undergoing surgery for CTS in routine clinical practice in the Russian Federation In order to achieve primary objective, the proportion of patients with confirmed diagnosis of ATTR PN (presence of TTR gene mutation according to the results of molecular genetic testing and clinical symptoms and/or signs of polyneuropathy) among those who underwent surgery for CTS will be calculated. Up to 12 months
Secondary To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at the onset of CTS symptoms up to 12 months
Secondary To assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the onset of polyneuropathy symptoms up to 12 months
Secondary to assess general demographic characteristics of patients with ATTR PN in Russia: Proportion of patients with late (>50 years) diagnosis of ATTR PN up to 12 months
Secondary to assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the time of CTS surgery up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number and proportion of patients with specific characteristic of index CTS download Left hand;
Right hand;
Both hands;
First procedure;
Second and later procedures
up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with CTS recurrence after surgery up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients undergoing repeat surgery for CTS after the index operation up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with PN progression after surgery up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with different number of red flags: 1 red flag;
2 red flags;
3 red flags;
4-5 red flags;
6-10 red flags;
>10 red flags;
up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean age (years) at ATTR PN diagnosis up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of women and men up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Mean body mass index (BMI) and proportion of patients with different BMI dimensions at the time of surgery and at Visit 1: Underweight (BMI <18.5 kg/m2);
Normal weight (BMI =18.5 and <25 kg/m2);
Overweight (BMI =25 and <30 kg/m2);
Obesity (BMI =30 kg/m2)
up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with a history of unexplained weight loss (=5 kg) at any point since symptom onset up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean and median time from CTS symptom onset (months) to ATTR PN diagnosis up to 12 months
Secondary To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of physicians seen since symptom onset before the correct ATTR PN diagnosis up to 12 months
Secondary To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of hospitalizations for PN before the correct ATTR PN diagnosis up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number of patients with previously established incorrect diagnosis according to medical records, specifically with: CIDP;
Lumbar/sacral radiculopathy;
Lumbar canal stenosis;
Paraproteinaemic peripheral neuropathy;
Chronic progressive sensory/sensorimotor axonal idiopathic PN;
AL amyloidosis;
Fibromyalgia;
Other (specify)
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with family history of neuropathic disease up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific peripheral neurological manifestations: Neuropathic pain (allodynia, hyperalgesia);
Progressive sensory disturbances (loss of temperature, pain, other sensation);
Paresthesia, dysesthesia;
Progressive motor disturbances;
Walking difficulty, gait disorder;
Balance disorder
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific Polyneuropathy Disability (PND) classes: 0;
I;
II;
IIIA;
IIIB;
IV;
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Proportion of patients with specific distribution of polyneuropathy symptoms: Upper-limb;
Lower-limb;
Both upper-limb and lower-limb
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with autonomic neurological manifestations, including specifically: Orthostatic hypotension;
Syncope;
Gastrointestinal motility disorders - i. Constipation; ii. Early satiety; iii. Diarrhea; iv. Nausea, vomiting;
Erectile dysfunction;
Neurogenic bladder;
Recurrent urinary infections;
Anhidrosis;
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant cardiac manifestations, including specifically: Left ventricular hypertrophy;
Left bundle branch block;
Atrioventricular block;
Heart failure with preserved ejection fraction;
Elevated serum N-terminal-proB-type natriuretic peptide (NT-proBNP) concentration;
Cardiac valve stenosis;
Cardiac valve regurgitation;
Tachyarrhythmia;
Other (specify);
None;
up to 12 months
Secondary Number of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit: Angiotensin converting enzyme inhibitor (ACEI) (specify);
Angiotensin receptor blocker (ARB) (specify);
Angiotensin receptor and neprilysin inhibitor (ARNI);
Sodium-glucose transporter type 2 inhibitor (SGLT2i) (specify);
Mineralocorticoid receptor antagonist (MRA) (specify);
Beta-blocker (specify);
Diuretic (specify);
Other cardiovascular (CV) medications (specify);
Other (specify);
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant ophthalmologic manifestations, including specifically Vitreous body inclusions (opacification);
Glaucoma;
Abnormal conjunctival vessels;
Papillary abnormalities;
Dry eye;
Other (specify);
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant musculoskeletal manifestations, including specifically: Spinal stenosis;
Osteoarthritis, including hip and knee arthroplasty;
Trigger finger;
Charcot's joints;
Biceps tendon rupture;
Rotator cuff injury;
Other (specify);
up to 12 months
Secondary Mean and median serum NT-proBNP (pg/ml) concentration up to 12 months
Secondary Proportion of patients with laboratory confirmed paraproteinemia up to 12 months
Secondary Mean and median urine albumin-creatinine ratio (UACR, mg/g of creatinine) up to 12 months
Secondary Proportion of patients with diagnosed CKD, including specifically Stage C1;
Stage C2;
Stage C3a;
Stage C3b;
Stage C4;
Stage C5;
up to 12 months
Secondary Number of patients with concomitant renal dysfunction, including specifically Elevated SCr level (based on the local laboratory reference range);
Decreased eGFR (<60 ml/min/1.73m2);
Presence of albuminuria (=30 mg/g creatinine (=30 mg/g of creatinine or =30 mg/24h);
Presence of proteinuria (according to urinalysis results);
Ultrasound signs of amyloid nephropathy;
up to 12 months
Secondary Number of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results up to 12 months
Secondary Mean and median measured peripheral sensory nerve conduction velocities Left Medial;
Left Ulnar;
Left Sural;
Right Medial;
Right Ulnar;
Right Sural;
up to 12 months
Secondary Number of patients with reduced peripheral sensory nerve conduction velocity at =1 site up to 12 months
Secondary Mean and median measured peripheral motor nerve conduction velocities Left Medial;
Left Ulnar;
Left Tibial;
Left Peroneal;
Right Medial;
Right Ulnar;
Right Tibial;
Right Peroneal;
up to 12 months
Secondary Number of patients with reduced motor sensory nerve conduction velocity at =1 site up to 12 months
Secondary Mean and median measured sensory action potential (SAP) amplitudes Left Medial;
Left Ulnar;
Left Sural;
Right Medial;
Right Ulnar;
Right Sural
up to 12 months
Secondary Number of patients with reduced/absent SAP amplitude at =1 site up to 12 months
Secondary Mean and median measured distal compound muscle action potential (dCMAP) amplitudes Left Medial;
Left Ulnar;
Left Tibial;
Left Peroneal;
Right Medial;
Right Ulnar;
Right Tibial;
Right Peroneal
up to 12 months
Secondary Mean and median measured proximal compound muscle action potential (pCMAP) amplitudes Left Medial;
Left Ulnar;
Left Tibial;
Left Peroneal;
Right Medial;
Right Ulnar;
Right Tibial;
Right Peroneal
up to 12 months
Secondary Number of patients with reduced/absent dCMAP amplitude at =1 site up to 12 months
Secondary Number of patients with reduced/absent pCMAP amplitude at =1 site up to 12 months
Secondary Proportion of patients with each score by each parameter of neurological examination up to 12 months
Secondary Number of patients in the specific categories of the modified Rankin scale Score 1 (no significant disability);
Score 2 (slight disability);
Score 3 (moderate disability);
Score 4 (moderately severe disability);
Score 5 (severe disability);
up to 12 months
Secondary Proportion of patients with specific number of points according to Inflammatory Neuropathy Cause and Treatment (INCAT) upper extremity scale 0 points;
1 point;
2 points;
3 points;
4 points;
5 points
up to 12 months
Secondary Median number of points according to INCAT upper extremity scale up to 12 months
Secondary Proportion of patients with specific number of points according to INCAT lower extremity scale 0 points;
1 point;
2 points;
3 points;
4 points;
5 points
up to 12 months
Secondary Median number of points according to INCAT lower extremity scale up to 12 months
Secondary Mean and median number of points according to combined clinical and electrophysiological score up to 12 months
Secondary To describe data on the results of genetic testing for ATTR in CTS patients undergoing surgery:Number and proportion of patients with specific TTR gene mutations Val30Met;
Ile107Val;
Phe33Leu;
Ala81Val;
Ser23Asn;
Ala25Thr;
Val32Ala;
Thr40Asn;
Gly47Ala;
Glu54Gln;
Tyr69Phe;
Glu92Lys;
Thr119Met;
Other
up to 12 months
Secondary to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with previously established incorrect diagnosis according to medical records, specifically with: CIDP;
Lumbar/sacral radiculopathy;
Lumbar canal stenosis;
Paraproteinaemic peripheral neuropathy;
Chronic progressive sensory/sensorimotor axonal idiopathic PN;
AL amyloidosis;
Fibromyalgia;
Other (specify);
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with autonomic neurological manifestations, including specifically: manifestations, including specifically:
Orthostatic hypotension;
Syncope;
Gastrointestinal motility disorders - i. Constipation; ii. Early satiety; iii. Diarrhea; iv. Nausea, vomiting;
Erectile dysfunction;
Neurogenic bladder;
Recurrent urinary infections;
Anhidrosis;
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant cardiac manifestations, including specifically: Left ventricular hypertrophy;
Left bundle branch block;
Atrioventricular block;
Heart failure with preserved ejection fraction;
Elevated serum N-terminal-proB-type natriuretic peptide (NT-proBNP) concentration;
Cardiac valve stenosis;
Cardiac valve regurgitation;
Tachyarrhythmia;
Other (specify);
None;
up to 12 months
Secondary proportion of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit: Angiotensin converting enzyme inhibitor (ACEI) (specify);
Angiotensin receptor blocker (ARB) (specify);
Angiotensin receptor and neprilysin inhibitor (ARNI);
Sodium-glucose transporter type 2 inhibitor (SGLT2i) (specify);
Mineralocorticoid receptor antagonist (MRA) (specify);
Beta-blocker (specify);
Diuretic (specify);
Other cardiovascular (CV) medications (specify);
Other (specify);
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant ophthalmologic manifestations, including specifically Vitreous body inclusions (opacification);
Glaucoma;
Abnormal conjunctival vessels;
Papillary abnormalities;
Dry eye;
Other (specify);
up to 12 months
Secondary To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant musculoskeletal manifestations, including specifically: Spinal stenosis;
Osteoarthritis, including hip and knee arthroplasty;
Trigger finger;
Charcot's joints;
Biceps tendon rupture;
Rotator cuff injury;
Other (specify);
up to 12 months
Secondary proportion of patients with concomitant renal dysfunction, including specifically Elevated SCr level (based on the local laboratory reference range);
Decreased eGFR (<60 ml/min/1.73m2);
Presence of albuminuria (=30 mg/g creatinine (=30 mg/g of creatinine or =30 mg/24h);
Presence of proteinuria (according to urinalysis results);
Ultrasound signs of amyloid nephropathy;
up to 12 months
Secondary proportion of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results up to 12 months
Secondary proportion of patients with reduced peripheral sensory nerve conduction velocity at =1 site up to 12 months
Secondary proportion of patients with reduced motor sensory nerve conduction velocity at =1 site up to 12 months
Secondary proportion of patients with reduced/absent SAP amplitude at =1 site up to 12 months
Secondary proportion of patients with reduced/absent dCMAP amplitude at =1 site up to 12 months
Secondary proportion of patients with reduced/absent pCMAP amplitude at =1 site up to 12 months
Secondary proportion of patients in the specific categories of the modified Rankin scale -a) Score 1 (no significant disability); b) Score 2 (slight disability); c) Score 3 (moderate disability); d) Score 4 (moderately severe disability); e) Score 5 (severe disability up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT05067205 - Minimal Invasive Carpal Tunnel Release With the Novel Device N/A
Completed NCT03184688 - Platelet Rich Plasma for Carpal Tunnel Syndrome N/A
Completed NCT03582735 - Preoperative Neuromobilization Exercises for Individuals With Carpal Tunnel Syndrome N/A
Completed NCT05490420 - Effects of Upper Extremity Manual Lymphatic Drainage on Symptom Severity, Hand Functions, Electrophysiological and Ultrasonographic Measurements in Carpal Tunnel Syndrome N/A
Recruiting NCT05970692 - Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of Atroshi-Lyrén 6-item Symptoms Scale
Completed NCT04043780 - Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome N/A
Completed NCT03880812 - Cost Information on Carpal Tunnel Syndrome Treatment Decisions N/A
Completed NCT06464809 - Treatment Intervention of Patients With Carpal Tunnel Syndrome (CTS) N/A
Recruiting NCT05328180 - aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) N/A
Recruiting NCT05372393 - Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block N/A
Recruiting NCT05503719 - An Absorbable Suture Versus a Non-absorbable Suture in Carpal Tunnel Release, a Randomized Controlled Trial N/A
Recruiting NCT05466162 - Soft Tissue Massage Along With Mobilization Technique on Symptoms and Functional Status of Carpal Tunnel Syndrome N/A
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Not yet recruiting NCT06294821 - 4AP to Delay Carpal Tunnel Release (CTR) Phase 2/Phase 3
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Terminated NCT02791529 - Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release Phase 1
Completed NCT02141035 - Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome Phase 2/Phase 3
Completed NCT01887145 - Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome N/A
Recruiting NCT01897272 - Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study N/A
Completed NCT01394822 - Neuromuscular Ultrasound for Focal Neuropathies N/A